Experimental and Therapeutic Medicine · 2021 · 11 citations · 21 references
Life SciencesCell BiologyMolecular BiologyCell SignalingInflammationSignal TransductionEndothelial ActivationEndothelial DysfunctionInflammatory MediatorsInflammatory Response RegulationInflammatory SignalingMetabolic InflammationAtherosclerosis Molecular MechanismsCell CountingCell Viability AssaysImmunofluorescence AssaysImmunofluorescence StainingNitric OxideVascular Endothelial DysfunctionWestern Blot Analysis
Oxidized low-density lipoprotein (ox-LDL)-induced endothelial dysfunction contributes to the progression of atherosclerosis. Interferon regulatory factor 2-binding protein 2 (IRF2BP2) attenuates macrophage-mediated inflammation and susceptibility to atherosclerosis. However, the effects of IRF2BP2 on vascular endothelial cells in atherosclerosis have not been fully elucidated. In the present study, the effects of IRF2BP2 on cell viability, inflammation and endothelial-to-mesenchymal transition (EMT) of human umbilical vein endothelial cells (HUVECs) were assessed using Cell Counting Kit-8 (CCK-8) assays, ELISA kits and western blot analysis, respectively. In addition, the expression levels of Krüppel-like factor 2 (KLF2) were determined by reverse transcription-quantitative PCR and immunofluorescence assays. A Nitrate/Nitrite assay kit was utilized to detect the production of nitric oxide (NO). The results demonstrated that ox-LDL induced inflammation and EMT of HUVECs, and decreased the NO levels. Furthermore, IRF2BP2 overexpression protected HUVECs against ox-LDL-induced inflammation, EMT and endothelial dysfunction, and resulted in upregulated expression of KLF2. Additionally, IRF2BP2 was shown to bind to KLF2, and KLF2 knockdown reversed the protective effects of IRF2BP2 on ox-LDL-exposed HUVECs. These findings indicated that IRF2BP2 may prevent ox-LDL-induced endothelial damage via upregulating KLF2 expression.
21
Joep Perk, Guy De Backer, H. Gohlke et al. · European Heart Journal · 2012 · 8.5K citations · Full text
A major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Myron I. Cybulsky, Kaeko Iiyama, Hongmei Li et al. · Journal of Clinical Investigation · 2001 · 1.2K citations · Full text
Endothelial-to-mesenchymal transition drives atherosclerosis progression
Pei‐Yu Chen, Lingfeng Qin, Nicolas Baeyens et al. · Journal of Clinical Investigation · 2015 · 585 citations · Full text
Cerebral cavernous malformations arise from endothelial gain of MEKK3–KLF2/4 signalling
Zinan Zhou, Alan T. Tang, Weng-Yew Wong et al. · Nature · 2016 · 321 citations